Latest Insider Transactions at Sera Prognostics, Inc. (SERA)
This section provides a real-time view of insider transactions for Sera Prognostics, Inc. (SERA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of SERA PROGNOSTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of SERA PROGNOSTICS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 06
2023
|
Robert Gardner Harrison Chief Information Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+44.88%
|
-
|
|
Nov 06
2023
|
Benjamin Jackson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+43.45%
|
-
|
|
Nov 06
2023
|
Zhenya Lindgardt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
975,000
+32.61%
|
-
|
|
Nov 06
2023
|
Paul Kearney Chief Data Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+43.1%
|
-
|
|
Nov 06
2023
|
John J. Boniface Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+39.13%
|
-
|
|
Nov 06
2023
|
Austin Aerts Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
335,000
+38.08%
|
-
|
|
Jun 05
2023
|
Robert Gardner Harrison Chief Information Officer |
SELL
Open market or private sale
|
Direct |
5,000
-14.93%
|
$15,000
$3.23 P/Share
|
|
Apr 06
2023
|
Paul Kearney Chief Data Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,050
+37.52%
|
$0
$0.75 P/Share
|
|
Mar 07
2023
|
Gregory C Critchfield Director |
BUY
Grant, award, or other acquisition
|
Direct |
62,200
+6.77%
|
-
|
|
Mar 06
2023
|
Paul Kearney Chief Data Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
-
|
|
Mar 06
2023
|
John J. Boniface Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,100
+24.14%
|
-
|
|
Mar 06
2023
|
Jay M Moyes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,800
+47.93%
|
-
|
|
Mar 06
2023
|
Benjamin Jackson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
24,700
+43.03%
|
-
|
|
Mar 06
2023
|
Robert Gardner Harrison Chief Information Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,500
+50.0%
|
-
|
|
Mar 06
2023
|
Michael R Foley Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,000
+50.0%
|
-
|
|
Mar 06
2023
|
Nadia Altomare Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,300
+50.0%
|
-
|
|
Sep 08
2022
|
John J. Boniface Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
844
+1.75%
|
$0
$0.73 P/Share
|
|
Jul 27
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,000
-2.1%
|
$2,000
$2.22 P/Share
|
|
Jul 27
2022
|
John J. Boniface Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+2.06%
|
$0
$0.73 P/Share
|
|
Jul 26
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-5.53%
|
$5,450
$2.15 P/Share
|
|
Jul 19
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-5.24%
|
$2,725
$1.86 P/Share
|
|
Jul 18
2022
|
Blue Ox Healthcare Partners, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
3,538,485
-93.39%
|
-
|
|
Jul 12
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-4.98%
|
$2,725
$1.84 P/Share
|
|
Jul 05
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-4.75%
|
$2,725
$1.63 P/Share
|
|
Jun 29
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,000
-1.71%
|
$1,000
$1.72 P/Share
|
|
Jun 29
2022
|
John J. Boniface Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.68%
|
$0
$0.73 P/Share
|
|
Jun 28
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-4.53%
|
$2,725
$1.89 P/Share
|
|
Jun 21
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-4.34%
|
$2,725
$1.31 P/Share
|
|
Jun 14
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-4.15%
|
$2,725
$1.21 P/Share
|
|
Jun 14
2022
|
Benjamin Jackson General Counsel |
BUY
Open market or private purchase
|
Direct |
8,000
+50.0%
|
$8,000
$1.2 P/Share
|
|
Jun 07
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-3.99%
|
$2,725
$1.3 P/Share
|
|
Jun 01
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,000
-1.44%
|
$1,000
$1.36 P/Share
|
|
Jun 01
2022
|
John J. Boniface Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.42%
|
$0
$0.73 P/Share
|
|
May 31
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-3.84%
|
$2,725
$1.45 P/Share
|
|
May 24
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-3.69%
|
$2,725
$1.54 P/Share
|
|
May 17
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-3.56%
|
$2,725
$1.55 P/Share
|
|
May 10
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-3.44%
|
$2,725
$1.97 P/Share
|
|
May 04
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,000
-1.25%
|
$2,000
$2.17 P/Share
|
|
May 04
2022
|
John J. Boniface Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.23%
|
$0
$0.73 P/Share
|
|
May 03
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-3.33%
|
$5,450
$2.17 P/Share
|
|
Apr 26
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-3.22%
|
$5,450
$2.17 P/Share
|
|
Apr 19
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-3.12%
|
$5,450
$2.08 P/Share
|
|
Apr 12
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-3.02%
|
$5,450
$2.66 P/Share
|
|
Apr 06
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,000
-1.1%
|
$3,000
$3.02 P/Share
|
|
Apr 06
2022
|
John J. Boniface Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.09%
|
$0
$0.73 P/Share
|
|
Apr 05
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-2.94%
|
$8,175
$3.35 P/Share
|
|
Mar 29
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-2.85%
|
$8,175
$3.73 P/Share
|
|
Mar 22
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-2.77%
|
$8,175
$3.68 P/Share
|
|
Mar 14
2022
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,725
-2.7%
|
$8,175
$3.94 P/Share
|
|
Mar 11
2022
|
John J. Boniface Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,998
+42.93%
|
$0
$0.73 P/Share
|